Medication info
Sitagliptin Metformin Extended-Release Tablets 100/1000 mg

Sitagliptin Metformin Extended-Release Tablets 100/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.37mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Bright blue, bilaterally convex oval extended-release film-coated tablets
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300592 · Approved 2023.02.17 · Insurance code 648508180

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this medication 100/1000 mg extended-release tablet once daily. Patients taking this medication 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is inadequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - For patients whose blood glucose is inadequately controlled with metformin monotherapy, the recommended initial total daily dose of this medication is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablets once daily. 3. Patients with inadequate blood glucose control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial metformin dose should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used alongside diet and exercise to assist patients with type 2 diabetes in controlling their blood sugar levels. It contains both sitagliptin and metformin, which help to effectively manage blood sugar. It is suitable for patients who have difficulty managing their blood glucose levels and contributes to the stable maintenance of blood sugar levels. This may improve symptoms of diabetes and have a positive effect on the prevention of complications. This medication improves blood sugar control in type 2 diabetes.

How to take

Adult dose

In antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this medication 100/1000 mg extended-release tablet once daily. Patients taking this medication 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is inadequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - For patients whose blood glucose is inadequately controlled with metformin monotherapy, the recommended initial total daily dose of this medication is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablets once daily. 3. Patients with inadequate blood glucose control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial metformin dose should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.

Precautions

This medication contains sitagliptin and metformin, which are used for the treatment of diabetes. Firstly, when taking this medication, severe allergic reactions may occur, so if symptoms such as skin rash, hives, or difficulty breathing appear, discontinue the medication immediately and consult a doctor. Also, acute pancreatitis, a serious inflammation of the pancreas, may rarely occur, so if abdominal pain or vomiting occurs, you should promptly inform medical personnel. The metformin included in this medication may pose risks for patients with decreased kidney function, so regular checks on kidney function should be conducted, and it should not be taken if there is severe renal disease or acute renal failure. Especially avoid taking this medication during conditions that can affect kidney function, such as dehydration, severe infections, heart disease, or sepsis, or temporarily discontinue it. It is not recommended for use in pregnant or breastfeeding women, or in children under 18 years of age. During the medication period, you should be aware of hypoglycemic symptoms, particularly if taken with insulin or sulfonylureas, as the risk of hypoglycemia may increase, so blood sugar should be checked frequently. Additionally, this medication may cause gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain, so please be advised. Before and after surgery or exams using radiographic contrast agents, this medication should be temporarily discontinued and resumed only after confirming normal kidney function. You should avoid excessive alcohol consumption while taking this medication, as alcohol can increase the risk of lactic acidosis, a side effect of this medication. Finally, it is important to have regular blood tests and kidney function assessments, as well as checking vitamin B12 levels during the course of treatment. By adhering to these precautions, this medication can assist in managing diabetes.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 20 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • hypoglycemia
  • severe hypoglycemia
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzyme levels

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It should not be stored in excessively cold or hot places and should be kept at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright blue, bilaterally convex oval extended-release film-coated tablets

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.